Management of cutaneous melanoma at the Joliot Curie Institute in Dakar

Authors

  • Jean Claude Balegana
  • Sidy Ka
  • Doudou Diouf
  • Jaafar Thiam
  • Mamadou Moustapha Dieng
  • Papa Macoumba Gaye
  • Mamadou Diop
  • Ahmadou Dem

DOI:

https://doi.org/10.54266/ajo.1.2.52.XRGI9314

Keywords:

Melanoma, Joliot Curie Institute, Dakar

Abstract

INTRODUCTION: The aim of this work is to study the clinical and therapeutic aspects of cutaneous melanoma at the Joliot Curie Institute of Dakar. PATIENTS AND METHODS: We performed a retrospective, descriptive and critical study at the Joliot Curie Institute of Dakar including all histologically confirmed melanoma cases between January 2008 and December 2013. RESULTS: During the study period, 21 cases were managed. The location was plantar in 76% of cases. Acral type was found in 85.7% of cases. All patients had a Clark level of IV or higher with a Breslow index of more than two mm. Fourteen patients underwent excision surgery and 12 had inguinal lymph node dissection. The average follow-up was 16 months with an overall survival of 58.7% at six months and 51% at one year. CONCLUSION: The majority of patients have benefited from surgical treatment, without prescription of immunotherapy which to date has revolutionized the management of advanced melanoma.

References

Globocan 2012.

Pitche P, Tchamdja S, Napo-Koura G, Bakonde P, Kpodzro K, Tchangaï-Walla K. Les cancers cutanés en consultation dermatologique à Lomé (Togo). Médecine d’Afrique Noire. 1997;44(1):15‑7.

Saka B, Souley Z, Kombate K, Mouhari-Touré A, Akakpo S, Napo-Koura G, et al. Les cancers cutanés au Togo: 223 observations. Médecine Tropicale. 2010;70(2):169‑71.

Moa S, Ah R. Pattern of cutaneous malignant melanoma in Zaria, Nigeria. Annals of African Medicine. 2006;5(1):16‑9.

Giles GG, Armstrong BK, Burton RC, Staples MP, Thursfield VJ. Has mortality from melanoma stopped rising in Australia? Analysis of trends between 1931 and 1994. BMJ. 4 mai 1996;312(7039):1121‑5. DOI: 10.1136/bmj.312.7039.1121

Maraninchi D, Cerf N, Bousquet P. Dynamique d’évolution des taux de mortalité des principaux cancers en France, Institut national du cancer. Paris, France; 2010 nov p. 47‑8.

Bulliard J, Panizzon R, Levi F. Epidémiologie et prévention du mélanome cutané en Suisse. Forum Med Suisse [Internet]. 22 avr 2009 [cité 27 févr 2024];9(17). Disponible sur: https://doi.emh.ch/fms.2009.06809. DOI: 10.4414/fms.2009.06809

for and on behalf of the Scottish Melanoma Group, MacKie RM, Bray C, Vestey J, Doherty V, Evans A, et al. Melanoma incidence and mortality in Scotland 1979–2003. Br J Cancer. juin 2007;96(11):1772‑7. DOI: 10.1038/sj.bjc.6603801

Tarwate M, Benchikhi H, Adarmouch L, Benider A, Amine M, Zamiati S, et al. Mélanome cutané épais: facteurs de mortalité et de survenue de métastases. Pan Afr Med J [Internet]. 2014 [cité 27 févr 2024];18. Disponible sur: http://www.panafrican-med-journal.com/content/article/18/44/full/ DOI: 10.11604/pamj.2014.18.44.2812

Soua Y, Chaabane H, Meziou TJ, Mesrati H, Khemakhem M, Mseddi M, et al. Profil anatomoclinique du mélanome dans le sud tunisien. Annales de Dermatologie et de Vénéréologie. déc 2011;138(12):A287. DOI: 10.1016/j.annder.2011.10.384

Mohammed AZ, Manasseh AN, Madong BM, Edino ST. Histopathological study of malignant melanoma in highlanders. Nigerian Journal of Surgical Research. juin 2003;5(1):18‑22.

Howlett AL, Dewar RA, Morris SF. The Epidemiology of Cutaneous Malignant Melanoma in Nova Scotia. Canadian Journal of Plastic Surgery. déc 2006;14(4):211‑4. DOI: 10.1177/229255030601400409

Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R, et al. Sentinel-Node Biopsy or Nodal Observation in Melanoma. N Engl J Med. 28 sept 2006;355(13):1307‑17. DOI: 10.1056/NEJMoa060992

Long GV, Stroyakovskiy D, Gogas H, Levchenko E, De Braud F, Larkin J, et al. Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. N Engl J Med. 13 nov 2014;371(20):1877‑88. DOI: 10.1056/NEJMoa1406037

Robert C, Long GV, Schachter J, Arance A, Grob JJ, Mortier L, et al. Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment. JCO. 20 mai 2017;35(15_suppl):9504‑9504. DOI: 10.1200/JCO.2017.35.15_suppl.9504

Published

01.07.2021

How to Cite

1.
Balegana JC, Ka S, Diouf D, Thiam J, Dieng MM, Gaye PM, et al. Management of cutaneous melanoma at the Joliot Curie Institute in Dakar. Af J Oncol [Internet]. 2021 Jul. 1 [cited 2024 Mar. 29];1(2):52-5. Available from: https://ojs.africanjournalofoncology.com/index.php/test/article/view/17

Issue

Section

Original articles